A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer

T Gulliford, J English, K W Colston, P Menday, S Moller, R C Coombes, T Gulliford, J English, K W Colston, P Menday, S Moller, R C Coombes

Abstract

Preclinical studies have shown that the vitamin D analogue EB 1089 has significantly less calcaemic activity than its parent compound 1,25-dihydroxyvitamin D (1,25(OH)2D3) and significant anti-tumour activity. This phase I trial was designed to evaluate the calcaemic effect of the drug in patients with advanced cancer. EB 1089 was given to 36 patients with advanced breast and colorectal cancer in doses of between 0.15 and 17.0 microg m(-2) day(-1). Serial serum and urine calcium, urine creatinine and serum parathyroid hormone (PTH) were monitored. Hypercalcaemia was seen in all patients receiving 17.0 microg m(-2) day(-1). Hypercalcaemia attributable to EB 1089 was reversible by discontinuing or reducing EB 1089 therapy. During the first 5 days of treatment, urine calcium (P = 0.0001) and serum-corrected calcium (P = 0.027) were related to EB 1089 dose, whereas serum parathyroid hormone (P = 0.0001) showed an inverse relationship. Twenty-one patients received compassionate treatment for between 10 and 234 days. No complete or partial responses were seen. Six patients on treatment for more than 90 days showed stabilization of disease. EB 1089 was well tolerated and adverse events considered to be caused by EB 1089 were limited to dose-dependent effects on calcium metabolism. The dose estimated to be tolerable for most patients from this study is around 7 microg m(-2) day(1). These data support previous work that has demonstrated EB 1089 to be significantly less calcaemic than 1,25-dihydroxyvitamin D3.

References

    1. Endocrinology. 1983 Dec;113(6):1950-7
    1. Proc Natl Acad Sci U S A. 1983 Oct;80(19):5907-11
    1. Int J Cancer. 1987 Jan 15;39(1):1-5
    1. Cancer Res. 1987 Dec 15;47(24 Pt 1):6793-9
    1. Biochem Pharmacol. 1988 Mar 1;37(5):889-95
    1. J Steroid Biochem. 1988 Feb;29(2):265-70
    1. Miner Electrolyte Metab. 1988;14(2-3):158-62
    1. Clin Nephrol. 1990 Feb;33(2):98-102
    1. Proc Natl Acad Sci U S A. 1990 May;87(10):3929-32
    1. Biometrics. 1990 Mar;46(1):33-48
    1. Cancer Res. 1990 Nov 1;50(21):6857-64
    1. Lancet. 1991 Jan 26;337(8735):193-6
    1. Lancet. 1991 Mar 23;337(8743):701-2
    1. Bone Miner. 1990 Dec;11(3):267-72
    1. J Cell Biochem. 1992 May;49(1):46-52
    1. Biochem Pharmacol. 1992 Dec 15;44(12):2273-80
    1. Gut. 1992 Dec;33(12):1660-3
    1. Endocrinology. 1993 May;132(5):1952-60
    1. J Clin Invest. 1993 Jun;91(6):2416-22
    1. Cancer Lett. 1993 Nov 30;75(1):35-9
    1. Clin Exp Metastasis. 1994 May;12(3):195-202
    1. J Endocrinol. 1994 Jun;141(3):555-63
    1. Blood. 1994 Sep 15;84(6):1960-7
    1. C R Acad Sci III. 1994 Mar;317(3):282-6
    1. Nutr Rev. 1994 Nov;52(11):376-82
    1. Eur J Biochem. 1995 Aug 1;231(3):517-27
    1. J Mol Endocrinol. 1995 Jun;14(3):391-4
    1. Cell. 1995 Dec 15;83(6):835-9
    1. Cancer Res. 1996 Aug 1;56(15):3570-6
    1. Dis Colon Rectum. 1997 Mar;40(3):317-21
    1. Biochem Med. 1978 Aug;20(1):23-30
    1. Endocrinology. 1981 Mar;108(3):1083-6
    1. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990-4
    1. Cancer Res. 1983 Sep;43(9):4443-7
    1. Cancer Res. 1987 Jan 1;47(1):21-5

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir